Selecta Biosciences Inc. (NASDAQ:SELB) saw an upside of 1.17% to close Tuesday at $4.34 after adding $0.05 on the day. The 5-day average trading volume is 558,580 shares of the company’s common stock. It has gained $4.51 in the past week. An average of 894,015 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 849,488.
SELB’s 1-month performance is 0.23% or -$0.07 on its low of $3.90 reached on 09/15/21. The company’s shares have touched a 52-week low of $1.96 and high of $5.70, with the stock’s rally to the 52-week high happening on 02/03/21. YTD, SELB has achieved 43.23% or $1.31. However, the current price is down -23.86%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Sep 02, 41 days have gone by since the last insider trading activity for Selecta Biosciences Inc. (SELB). Brunn Carsten (President and CEO) most recently sold 4,523 shares at $4.51 per share on Sep 02. This transaction cost the insider $20,399. President and CEO, Brunn Carsten, sold 4,806 shares at a price of $4.38 on Jun 02. Then, on Mar 17, COO and SVP, R&D Johnston Lloyd P. sold 15,128 shares at a price of $4.45 per share. This transaction amounted to $67,312.
Selecta Biosciences Inc. (SELB) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.SELB stock has a beta of 1.10. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.51 while the price to cash flow ratio at 12.71.
Selecta Biosciences Inc.’s quick ratio for the period ended June 29 was 1.90, with the current ratio over the same period at 1.90 meaning that SELB stock is able to fulfill its debt obligations. The trailing 12-month EBITDA margin is -331.95% while for the period ending June 29; Selecta Biosciences Inc.’s operating margin was -60.70%. The firm’s gross profit as reported stood at $73.42 million against revenue of $16.6 million.
For the quarterly period ending June 29 this year, Selecta Biosciences Inc.’s cash and short-term investments amounted to $24.39 million against total debt of $35.34 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 100.0% to $19.66 million, while revenue of $11.05 million was 43.79% off the previous quarter. Analysts expected SELB to announce -$0.12 per share in earnings in its latest quarter, but it posted $0.04, representing a 133.30% surprise. EBITDA for the quarter stood at more than $0.77 million. SELB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 184.74 million, with total debt at $35.34 million. Shareholders hold equity totaling $115.08 million
Let’s look briefly at Selecta Biosciences Inc. (SELB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 54.83% to suggest the stock is trending Neutral, with historical volatility in this time period at 23.30%.
The stock’s 5-day moving average is $4.27, reflecting a +0.23% or $0.01 change from its current price. SELB is currently trading +8.23% above its 20-day SMA, +36.91% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +22.60% and +32.72% respectively.
Stochastic %K and %D was 56.92% and 51.41% and the average true range (ATR) pointed at 0.20. The RSI (14) points at 53.29%, while the 14-day stochastic is at 63.92% with the period’s ATR at 0.22. The stock’s 9-day MACD Oscillator is pointing at 0.05 and 0.03 on the 14-day charts.
In the most recent analyst report for Selecta Biosciences Inc. (NASDAQ: SELB), BTIG Research launched coverage with a Buy rating. Analysts offering their rating for SELB stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate SELB as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is SELB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $13.00, with their median price target at $8.50. Looking at these predictions, the average price target given by analysts is for Selecta Biosciences Inc. (SELB) stock is $8.67.